A Phase 2 interventional study of Avacincaptad Pegol in Idiopathic Polypoidal Choroidal Vasculopathy, sponsored by Ophthotech Corporation. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by Ophthotech Corporation (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 2, and was the 12th registered.
54 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 6 are open to participants now.
Browse Polypoidal Choroidal Vasculopathy studies →1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 7–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 4 2
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 50 across 39 interventional studies indexed under Polypoidal Choroidal Vasculopathy.
Median enrollment 20 across the 12 interventional studies, 150 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Ophthotech Corporation, one of the names counted as Astellas Pharma Inc. Under that name alone:
Ophthotech Corporation is the lead sponsor of 13 studies on the registry; none are open to participants now.
Astellas Pharma Inc has 2 studies filed under Polypoidal Choroidal Vasculopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).
Treatment experienced (Prior treatment with anti-VEGF monotherapy of ≥8 injections in the previous twelve (12) months) subjects of either gender aged 50 years or above with a diagnosis of IPCV, will receive 3 monthly (Q4W) intravitreal injections of Zimura™ (1 mg/eye) in combination with anti-VEGF therapy (Avastin® 1.25 mg/eye or Lucentis® 0.5 mg/eye or Eylea® 2 mg/eye).
Safety endpoints include visual acuity loss (proportion of subjects with >15 letter loss at Month 3), ophthalmic adverse events (AEs), systemic adverse events (AEs), change in total retinal thickness (SD-OCT) at Month 3, regression and/or elimination of polyps at Month 3 compared to screening as measured by indocyanine green angiography (ICGA), and laboratory values.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with either Lucentis, Avastin or Eylea.
Drug: Avacincaptad Pegol
Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.
Also known as: Zimura (previous name), IZERVAY, Avastin, Eylea, Lucentis, ARC1905
Number of Participants With >15 ETDRS Letter Loss at Month 3
Number of participants with \>15 ETDRS letter loss (with calculated percentage)
Time frame: 3 Months
Number of Participants With Ophthalmic Adverse Events
Number of Participants with Ophthalmic Adverse Events (with calculated percentage)
Time frame: 3 months
Number of Participants With Systemic Adverse Events
Number of Participants with Systemic Adverse Events (with calculated percentage)
Time frame: 3 months
Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3
Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT
Time frame: Baseline and Month 3
Regression and/or Elimination of Polyps at Month 3
Regression and/or Elimination of Polyps from baseline to Month 3
Time frame: Baseline and Month 3
| Milestone | Zimura + Anti-VEGF |
|---|---|
| Started | 4 |
| Completed | 4 |
| Not completed | 0 |
Number of participants with \>15 ETDRS letter loss (with calculated percentage)
| Participants | Zimura + Anti-VEGF |
|---|---|
| Number of Participants With >15 ETDRS Letter Loss at Month 3 | 0 |
Number of Participants with Ophthalmic Adverse Events (with calculated percentage)
| Participants | Zimura + Anti-VEGF |
|---|---|
| Number of Participants With Ophthalmic Adverse Events | 3 |
Number of Participants with Systemic Adverse Events (with calculated percentage)
| Participants | Zimura + Anti-VEGF |
|---|---|
| Number of Participants With Systemic Adverse Events | 1 |
Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT
| μm | Zimura + Anti-VEGF |
|---|---|
| Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3 | -2.75 (-67 to 69) |
Regression and/or Elimination of Polyps from baseline to Month 3
| Polyps | Zimura + Anti-VEGF |
|---|---|
| Regression and/or Elimination of Polyps at Month 3 | NA |
Collected over 3 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zimura + Anti-VEGF | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Event | Zimura + Anti-VEGF |
|---|---|
| EndophthalmitisInfections and infestations | 1/4 |
| Event | Zimura + Anti-VEGF |
|---|---|
| Conjunctival haemorrhageEye disorders | 3/4 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 1/4 |
| Age, Continuous(years) | Zimura + Anti-VEGF |
|---|---|
| Mean | 74.5 ± 6.03 |
| Age, Customized(Participants) | Zimura + Anti-VEGF |
|---|---|
| Age — Adults 50-65 | 0 |
| Age — Adults >65-75 | 2 |
| Age — Adults >75 | 2 |
| Sex: Female, Male(Participants) | Zimura + Anti-VEGF |
|---|---|
| Female | 1 |
| Male | 3 |
| Region of Enrollment(participants) | Zimura + Anti-VEGF |
|---|---|
| United States | 4 |
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Mar 2015 to primary completion in Oct 2015, 7 months.
Results were first posted in Jan 2019, 3 years 3 months after primary completion. A results delay was requested in Apr 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avacincaptad pegol
Polypoidal Choroidal Vasculopathy →